First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01697072 |
Recruitment Status :
Terminated
(All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.)
First Posted : October 2, 2012
Last Update Posted : February 9, 2016
|
Sponsor:
Amgen
Information provided by (Responsible Party):
Amgen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Terminated |
---|---|
Actual Primary Completion Date : | November 2014 |
Actual Study Completion Date : | August 2015 |
Certification/Extension First Submitted : | October 22, 2015 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):